南京大学医学院-j9集团

南京大学医学院附属鼓楼医院血液内科副主任医师，副教授，博士生导师，医药生物技术国家重点实验室pi。

主要研究方向包括：1、血小板、干细胞等活细胞诊疗技术研发与转化；2、恶性血液病的复发机制及干预；3、基于人工智能的血液病个体化诊疗新方法。

本人近年来围绕血液肿瘤的生物治疗开展研究，共发表sci论文89篇，其中作为第一或通讯作者在nat commun, cell death differ, adv funct mater等高影响力期刊发表文章共56篇；参与编写血液学英文专著1部、中文专著1部；主持包括三项国家自然科学基金等项目十余项，目前在研课题包括1项国家级面上项目和1项国家重点研发计划子课题，可支配经费300余万元；申请专利13项（授权11项），1 项研究成果获得南京转化研究院重点培育项目进入孵化阶段（2020），牵头研究者发起的临床试验2项，研究成果被nature、顶级专业期刊blood及国际著名科技媒体nanotech等大幅引用及高度评价。

1.      中华医学会血液学分会青年委员会，委员

2.      江苏省医学会血液学分会青年委员会，副主任委员

3.      江苏省研究型医院协会浆细胞病专委会，委员兼秘书长

4.      江苏省医师协会遗传分会，委员

5.        南京市医学会血液学分会青年委员会，副主任委员

1.      overcoming hypoxia by multistage nano delivery system to inhibit mitochondrial respiration for photodynamic therapy. advanced functional materials, 2019, 29, 1807294 if=18.808

2.      ailoring the component of protein corona via simple chemistry,nature communication, 2019,10, 4520 if=14.919

3.      licochalcone a suppresses sp1 expression with potential anti-myeloma activity. cancer commun (lond). 2021,19 if=10.392

4.      doxorubicin-loaded platelets as a smart drug delivery system: an improved therapy for lymphoma. sci rep, 2017, 7, 42632 if=5.379

5.      ultrafast glucose-responsive, high loading capacity erythrocyte to self-regulate the release of insulin. acta biomaterialia, 2018, 69, 301-312 if=10.947

6.      platinum prodrug inhibiting tumor recurrence and metastasis by  concurrent chemo radiotherapy. journal of nanobiotechnology.(2022) 20:129. if=10.509

7.      anti-fas antibody conjugated nanoparticles enhancing the antitumor effect of camptothecin by activating the fas−fasl apoptotic pathway.acs appl mater inter. 2016;8(44):29950-29959. if=10.383

8.      screening t‑cell activity via a photodetachable dna-copolymer nanocage and its therapeutic application.analytical chemistry.2022,94, 38, 13205-13214. if=8.808

9.      overcoming the blood-brain barrier by using a multistage platelet delivery system to inhibit central nervous system lymphoma. nanomedicine: nanotechnology, biology and medicine.2022,01,15499634. if=8.458

10.   ultrafast glucose-responsive, high loading capacity erythrocyte to self-regulate the release of insulin. acta biomaterialia, 2018, 69, 301- 312 if=8.947

11.   prmt5 regulates cell pyroptosis by silencing casp1 in multiple myeloma, cell death disease. 2021,16;12(10):851 if=8.469

12.   novel two-chain structure utilizing kirs2/dap12 domain improves the safety and efficacy of car-t cells in adults with r/r b-all. mol ther oncolytics. 2021,28;23:96-106 if=7.200

13.   vincristine-loaded platelets coated with anti-cd41 mabs: a new proposal for the treatment of immune thrombocytopenia. biomater science, 2019, 7, 4568-4577 if=6.843

14.   nitroxide-radicals-modified gold nanorods for in vivo ct/mri-guided photothermal cancer therapy. int j nanomedicine. 2018, 13, 7123-7134 if=6.4

15.   daunorubicin-loaded cdte qds conjugated with anti-cd123 mabs: a novel delivery system for myelodysplastic syndromes treatment. int j nanomedicine. 2020, 15, 521-536 if=6.4

16.   acetazolamide-loaded ph-responsive nanoparticles alleviating tumor acidosis to enhance chemotherapy effects. macromolecular bioscience, 2019, 19(2): 11 if=4.979

17.   gene signatures and prognostic values of m6a-related genes in multiple myeloma. curr res transl med. 2021;69(2):103288 if=4.513

18.   identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma,cancer med,2021;10(20):7395-7403 if=4.45

19.   doxorubicin-loaded platelets as a smart drug delivery system: an improved therapy for lymphoma. sci rep, 2017, 7, 42632 if=4.379

20.   characteristics and mutation analysis of ph-positive leukemia patients with t315i mutation receiving tyrosine kinase inhibitors. oncotargets and therapy, 2017, 10: 4731-4738 if=4.147

21.   a centromere-associated gene score for rapid determination of risk in multiple myeloma. american journal of translational research. 2020, 12, 2425-2438 if=4.060

22.   bortezomib activation of mtorc1 pathway mediated by nox2-drived reactive oxygen species results in apoptosis in primary dorsal root ganglion neurons. experimental cell research.2021;400(2):112494 if=3.905

23.   pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. clinica chimica acta, 2018, 481, 34-41 if=3.786

24.   plp2 expression as a prognostic and therapeutic indicator in high-risk multiple myeloma. biomed res int, 2020, 4286101 if=3.411

25.   expression of mage-c1/ct7 provides prognostic information in multiple myeloma. leukemia & lymphoma, 2017, 58(1): 244-246 if=3.28

26.   mir-181a enhances drug sensitivity of mixed lineage leukemia- rearranged acute myeloid leukemia by increasing poly(adp-ribose) polymerase1 acetylation. leuk lymphoma. 2021;62(1):136-146 if=3.28

27.   effects of digoxin on cell cycle, apoptosis and nf-kappa b pathway in burkitt's lymphoma cells and animal model. leukemia & lymphoma, 2017, 58(7): 1673-1685 if=3.28

28.   tp53 mutation predicts the poor prognosis of non-hodgkin lymphomas: evidence from a meta-analysis. plos one, 2017, 12(4): 14 if=3.24

29.   anti-cd22-conjugated cdte qds co-loaded with doxorubicin and gambogic acid: a novel platform for lymphoma treatment. rsc advances, 2017, 7(54): 33905-33913 if=3.119

30.   correlation of mir- 181a and three hoxa genes as useful biomarkers in acute myeloid leukemia. int j lab hematol, 2020, 42, 16-22 if=2.877

31.   wogonin inhibits growth of mantle cell lymphoma cells, through nuclear factor-κb signaling pathway. chin med j, 2018, 4, 495-497 if=2.628

32.   development of follicular lymphoma after treatment of diffuse large b- cell lymphoma: two case reports with review of literature. international journal of experimental pathology. 2018, 11, 324-332 if=1.925

33.   successful management of a complicated clinical crisis: a patient with left- sided endocarditis and secondary hemophagocytic lymphohistiocytosis: a rare case report and literature review. medicine, 2017, 96(51): 5 if=1.84

34.   doxorubicin-loaded cus nanoparticles conjugated with gflg: a novel drug delivery system for lymphoma treatment. nano, 2019, 14(1):11 if=1.566

35.   ,higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma. translational cancer research, 2019, 8(5): 2099-2106 if=1.214

36.   refractory multiple myeloma with extramedullary plasmacytoma of the spleen and suspicious teratoma: a rare case report and literature review. int j clin exp pathol. 2021,15;14(4):455-462 if=0.805

1.      基于新型“car-血小板载药体系”的噬血细胞综合征免疫靶向治疗及机制研究，国家自然基金面上项目

2.      生物活体功能材料的疾病治疗应用，国家重点研发计划子课题

3.      激活休眠骨髓瘤细胞的作用及其机制研究，中央高校原创与交叉研究基金培育项目

4.      “333高层次人才”（第五期），江苏省人社厅

5.      可靶、可视、可控的外泌体载药体系的设计及其抗中枢淋巴瘤效应研究，南京市重点项目

6.      全反式维甲酸联合泼尼松对照泼尼松治疗初发/初治itp的前瞻性、单中心、随机、对照临床研究，南京鼓楼医院临床研究专项资金项目

7.      基于深度学习的显微高光谱图像血液肿瘤组织分类，华东师范大学上海市多维度信息处理重点实验室合作项目

1.      cd22-血小板-dox靶向载药系统的构建及其抗肿瘤效应研究，中华医学会第十六次全国血栓与止血会议“优秀大会发言”，二等奖，2017年

2.      中华医学会第十七次会议全国血栓与止血学术会议最佳论文奖，2019年

3.      血小板载化疗药物治疗恶性肿瘤的研究，江苏肿瘤医学科学技术奖，一等奖，2017年

4.      基于免疫识别的靶向血小板载药体系在血液肿瘤的应用，省部级最佳论文奖，一等奖，2019年

5.      基于人工智能的恶性血液病个体化诊疗策略体系构建与实施，省部级医学新技术引进奖，一等奖，2020年

6.      强心甾类固醇及纳米技术治疗淋巴系统肿瘤的基础及临床转化研究，南京市科学技术进步奖，三等奖，2017年